Oct. 23 at 6:00 PM
$CHRS From GROK. I asked if everything went right. where could the stock be in two years. I'll take 17X
Stock Price Projection for October 2027
Base Case (Multiples-Based): At
$230M 2027 revenue, apply 7x EV/Revenue =
$1.6B EV. Add
$400M net cash (from divestiture + profits). Market cap: ~
$2B →
$17/share (15x upside from
$1.13).
Bull Case (Full Success): If revenues hit
$300M+ (e.g., all combos approved), 8x multiple (premium for IO leadership) →
$2.4B EV + cash =
$21/share.
Scenario
2027 Revenue (
$M)
EV Multiple
Projected Price/Share
Upside from Current
Base (Success)
230 7x
$17 + 1,400%
Ultra-Bull
300+ 8x
$21 +1,760%
Consensus (Mild)
150 6x
$10 +785% .
Conclusion
If trials deliver clean data and toripalimab hits >
$100M revenues, CHRS could transform from a distressed micro-cap (~
$130M) to a
$2B+ mid-cap by late 2027, trading at
$17-
$21/share. This values the company at ~7-8x forward sales, in line with growth biotechs (e.g., peers like Exelixis at 6-9x).
